Add Yahoo as a preferred source to see more of our stories on Google. Weekly insulin shots can help control both Type 1 and Type 2 diabetes as well as daily injections do, a pair of clinical trials ...

A once-weekly insulin formulation called icodec performed just as well as daily doses of the insulin degludec, Phase 3 clinical trial results show. Photo by peter-facebook/Pixabay People with Type 2 ...

Please provide your email address to receive an email when new articles are posted on . A group of experts updated the FITTER insulin injection recommendations for the first time since 2016. The ...

An international expert panel has recently released a comprehensive set of recommendations for optimal insulin injection techniques and equipment. The group, called the Forum for Injection Technique ...

A real-world study conducted across 9 European countries found that bolus injection frequency and engagement with a smart pen to administer insulin were associated with improved glycemic control among ...

The primary factor behind diabetes is that your body may not make enough insulin (type 1 diabetes) or it fails to respond to the insulin your pancreas releases, which is known as insulin resistance ...

A major challenge for people who have a form of diabetes is the need to regulate the glucose levels in their body. Normally this is where the body’s insulin-producing cells would respond to glucose ...

A century ago, type 1 diabetes was a death sentence. Children diagnosed rarely survived more than a year or two, wasting away as their bodies starved despite food. Then, in 1921, in a modest lab in ...

Insulin icodec, a once-weekly basal injection to treat type 1 diabetes, has the potential to be as effective in managing the condition as daily basal insulin treatments, according to new research. The ...

Data were obtained through an Internet survey of U.S. adults self-identified as taking insulin to treat type 1 or type 2 diabetes; the survey was conducted 13 June to 7 July 2008 by Harris Interactive ...

A workplace text over a routine medical act raises sharp questions about privacy, disability rights and who must adapt.